"A RCT ON CLINICAL EFFICACY OF 1% vs. 2% LIGNOCAINE IN COUGH SUPPRESSION AND PAIN RELIEF IN PATIENTS UNDERGOING FLEXIBLE BRONCHOSCOPY"
Overview
- Phase
- Phase 2
- Intervention
- 1% lignocaine
- Conditions
- Lung Cancer
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Cough suppression (by Operator and Patient)
- Status
- Completed
- Last Updated
- 11 years ago
Overview
Brief Summary
Flexible bronchoscopy is a common procedure performed by pulmonary physicians. The use of topical anesthesia, analgesia, and sedation during flexible bronchoscopy varies among physicians, institutions and geographic locations across the globe. Commonly used topical anesthetic agents before and during bronchoscopy include cocaine (4%),benzocaine (20%), tetracaine (1%), and lignocaine (1%-10%). Topical lignocaine is administered through the flexible bronchoscope in an attempt to reduce excessive coughing and patient discomfort. However, the optimal dosage and strength of topical lignocaine that should be used during fibreoptic bronchoscopy has long been a topic of controversy. In this study we compare the efficacy of 1% versus 2% lignocaine in controlling cough and pain in patients undergoing flexible bronchoscopy.
Investigators
Ritesh Agarwal
Associate Professor
Post Graduate Institute of Medical Education and Research, Chandigarh
Eligibility Criteria
Inclusion Criteria
- •Consecutive patients undergoing flexible bronchoscopy
- •Hemodynamic stability
Exclusion Criteria
- •Patients receiving sedatives during the course of their treatment
- •Patients undergoing conventional TBNA and/or EBUS-TBNA who are likely to receive sedation
- •Patients with known hypersensitivity to lignocaine
- •Not willing to provide informed consent
Arms & Interventions
1% lignocaine
Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (1%) 8ml will be administered as "spray as you go" technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients.
Intervention: 1% lignocaine
2% lignocaine
Each patient included in study will be nebulized prior to flexible bronchoscopy with 2.5 ml of 4% lignocaine. This will be followed by spray of 2 puffs of 10% lignocaine over the posterior pharynx and vocal cords. Lignocaine jelly (2%) will be applied in the nasal cavity. Lignocaine (2%) 8ml will be administered as "spray as you go" technique through the bronchoscope over the vocal cords, carina, right and left main bronchus as aliquots of 2 ml each. Additional requirement of lignocaine will also be recorded for all the patients.
Intervention: 2% lignocaine
Outcomes
Primary Outcomes
Cough suppression (by Operator and Patient)
Time Frame: 15 minutes
Cough will be rated on a visual analog scale (VAS) from 0 (no cough) to 100 mm (worst cough ever)
Pain control
Time Frame: 15 minutes
Pain will be assessed on Wong Baker Face rating scale